Faron advances cancer immunotherapy with new co-operation
Finnish biopharmaceutical company Faron Pharmaceuticals has entered into an agreement with Swiss-based life science company Selexis.
Under the agreement, Faron will use Selexis’ technology platform for the production of high-expressing and stable clonal cell lines. They will be used in the development and production of Clevegen, Faron’s novel cancer immunotherapy antibody.
Immunotherapy leverages the patient’s own natural immune response to combat cancer. According to Faron, it offers enormous potential in the treatment of cancer and is one of the most actively pursued areas of research by biotechnology and pharmaceutical companies.
Clevegen targets a cell surface receptor called Clever-1. When Clever-1 is blocked, tumour-associated macrophages cannot enter the tumour site and their function in the tumour as an immune suppressive cell is diminished. Both these events change the tumour environment from immune suppression to immune stimulation, allowing the host immune system to fight the tumour cells.